Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
AstraZeneca
Fuji
Cantor Fitzgerald
Baxter
Chubb
Argus Health
Farmers Insurance

Generated: May 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,133,310

« Back to Dashboard

Summary for Patent: 6,133,310
Title: Method of treatment of rosacea
Abstract:A method of treatment of acne rosacea consists of the application, in the form of either a lotion or a cream, constituting a mixture of a therapeutically effective amount of invermectin in water, in the case of the lotion, and invermectin and a pharmaceutically acceptable carrier, in the case of the cream. Application to the affected area occurs daily for a period of one week and, thereafter, two to four times per month for a period of up to one year.
Inventor(s): Parks; L. Dean (Ocala, FL)
Assignee:
Application Number:09/383,594
Patent Claims: 1. A method of treatment of acne rosacea, consisting of the steps of:

(a) mixing a therapeutically effective amount of invermectin with water to thereby form a lotion;

(b) applying said lotion daily to an affected area for a period of about seven days; and

(c) repeating such application two to four times a month for a period of several months; and, optionally, repeating application of said lotion about once a month thereafter.

2. The method as recited in claim 1, in which said therapeutically effective amount of invemectin comprises a concentration of at least 750

mcg/ml.

3. A method of treatment of rosacea, consisting of the steps of:

(a) mixing a therapeutically effective amount of invermectin with a pharmaceutically acceptable carrier to thereby form a cream; applying said cream daily to an affected area for a period of about seven days; and

(b) repeating such application two to four times a month for a period of several months; and, optionally, repeating application of said cream about once a month thereafter.

4. The method as recited in claim 3 in which said therapeutically effective amount of invermectin comprise a concentration of at least 750 mcg/cc within said cream.

5. The method as recited in claim 4 in which said pharmaceutically acceptable carrier is selected from the group of carriers consisting of propylene glycol, sodium lauryl sulfate, xanthum gum, or combinations thereof.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Moodys
US Army
Cantor Fitzgerald
Medtronic
Colorcon
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.